Personalis
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 225
- Market Cap
- -
- Introduction
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.
Clinical Trials
1
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Conditions
- TNBC - Triple-Negative Breast CancerMinimal Residual Disease
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Personalis Inc.
- Target Recruit Count
- 422
- Registration Number
- NCT06230185
- Locations
- 🇺🇸
Arizona Oncology, Tucson, Arizona, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸George Washington University, Washington DC, District of Columbia, United States
News
Personalis to Present New Data on NeXT Personal ctDNA Test for Early Cancer Detection at Major Oncology Conferences
Personalis and academic collaborators will showcase new clinical data on their ultrasensitive NeXT Personal ctDNA assay at upcoming AACR and ASCO conferences, demonstrating its application across multiple cancer types.
Ultrasensitive ctDNA Test Predicts Relapse Risk and Survival in Early-Stage Lung Cancer
A new ultrasensitive ctDNA test, NeXT Personal, shows promise in predicting lung cancer relapse risk and overall survival in early-stage patients.
Ultra-Sensitive Blood Test Predicts Breast Cancer Recurrence Up to 41 Months Before Clinical Symptoms
A new ultra-sensitive liquid biopsy using whole genome sequencing can detect breast cancer recurrence an average of 15 months before clinical symptoms appear, with the longest lead time reaching 41 months.